{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T09:45:02Z","timestamp":1794217502991,"version":"4.8.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T00:00:00Z","timestamp":1636675200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016016","name":"Gilead Sciences Europe Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.lanepe.2021.100281","type":"journal-article","created":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T16:52:15Z","timestamp":1639241535000},"page":"100281","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Impact of extending direct antiviral agents (DAA) availability in France: an observational cohort study (2015-2019) of data from French administrative healthcare databases (SNDS)."],"prefix":"10.1016","volume":"13","author":[{"given":"Stanislas","family":"Pol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fayssoil","family":"Fouad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Lemaitre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Lada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascaline","family":"Rabiega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Benabadji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Roudot-Thoraval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lanepe.2021.100281_bib0001","unstructured":"WHO. Hepatitis C. http:\/\/www.who.int\/mediacentre\/factsheets\/fs164\/fr\/ (accessed Feb 17, 2020 )."},{"key":"10.1016\/j.lanepe.2021.100281_bib0002","first-page":"224","article-title":"Estimation de la pr\u00e9valence de l'h\u00e9patite C en population g\u00e9n\u00e9rale, France m\u00e9tropolitaine, 2011","volume":"13","author":"Pioche","year":"2016","journal-title":"Bull Epidemiol Hebd"},{"key":"10.1016\/j.lanepe.2021.100281_bib0003","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1002\/hep.1840360704","article-title":"Course and outcome of hepatitis C","volume":"36","author":"Hoofnagle","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.lanepe.2021.100281_bib0004","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nrgastro.2017.172","article-title":"Extrahepatic cancers and chronic HCV infection","volume":"15","author":"Pol","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.lanepe.2021.100281_bib0005","first-page":"165","article-title":"History and progress of antiviral drugs: From acyclovir to direct-acting antiviral agents (DAAs) for Hepatitis C","volume":"17","author":"Bryan-Marrugo","year":"2015","journal-title":"Med Univ"},{"key":"10.1016\/j.lanepe.2021.100281_bib0006","doi-asserted-by":"crossref","first-page":"ofx264","DOI":"10.1093\/ofid\/ofx264","article-title":"Direct-acting antivirals improve access to care and cure for patients with HIV and chronic HCV infection","volume":"5","author":"Collins","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.lanepe.2021.100281_bib0007","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","article-title":"Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study","volume":"393","author":"Carrat","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.lanepe.2021.100281_bib0008","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Recommandation du Coll\u00e8ge de la HAS, prise en charge de l'h\u00e9patite C par les m\u00e9dicaments anti-viraux \u00e0 action directe (AAD). Jul, 2014. https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/201407\/hepatite_c_prise_en_charge_anti_viraux_aad.pdf (accessed Apr 28, 2021)."},{"key":"10.1016\/j.lanepe.2021.100281_bib0009","unstructured":"Journal Officiel de la R\u00e9publique Fran\u00e7aise. Arr\u00eat\u00e9 du 18 novembre 2014 relatif aux conditions de prise en charge de sp\u00e9cialit\u00e9s pharmaceutiques disposant d'une autorisation de mise sur le march\u00e9 inscrites sur la liste vis\u00e9e \u00e0 l'article L. 5126-4 du code de la sant\u00e9 publique. NOR: AFSS1426759A ELI. 18 novembre 2014. https:\/\/www.legifrance.gouv.fr\/eli\/arrete\/2014\/11\/18\/AFSS1426759A\/jo\/texte (accessed Apr 28, 2021)"},{"key":"10.1016\/j.lanepe.2021.100281_bib0010","unstructured":"Journal Officiel de la R\u00e9publique Fran\u00e7aise. Arr\u00eat\u00e9 du 10 juin 2016 relatif aux conditions de prise en charge de sp\u00e9cialit\u00e9s pharmaceutiques disposant d'une autorisation de mise sur le march\u00e9 inscrites sur la liste vis\u00e9e \u00e0 l'article L. 5126-4 du code de la sant\u00e9 publique. NOR: AFSS1613575A ELI. https:\/\/www.legifrance.gouv.fr\/eli\/arrete\/2016\/6\/10\/AFSS1613575A\/jo\/texte. (accessed Apr 28, 2021)"},{"key":"10.1016\/j.lanepe.2021.100281_bib0011","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Recommandation du Coll\u00e8ge de la HAS, pris en charge de l'h\u00e9patite C par les m\u00e9dicaments antiviraux d'action directe (AA), \u00e9largissement du p\u00e9rim\u00e8tre de remboursemnet. https:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/201612\/recommandation_college_hepatite_c.pdf (accessed Apr 28, 2021 )."},{"key":"10.1016\/j.lanepe.2021.100281_bib0012","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"(EASL) recommendations on treatment of hepatitis C: final update of the series","volume":"73","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.lanepe.2021.100281_bib0013","unstructured":"AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. 2017. http:\/\/www.hcvguidelines.org (accessed Jul 16, 2017)."},{"key":"10.1016\/j.lanepe.2021.100281_bib0014","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1016\/j.respe.2017.05.004","article-title":"Value of a national administrative database to guide public decisions: from the syst\u00e8me national d'information interr\u00e9gimes de l'Assurance Maladie (SNIIRAM) to the syst\u00e8me national des donn\u00e9es de sant\u00e9 (SNDS) in France","volume":"65","author":"Tuppin","year":"2017","journal-title":"Rev Epidemiol Sante Publique"},{"key":"10.1016\/j.lanepe.2021.100281_bib0015","unstructured":"SOS H\u00e9patite. Campagne - savoir c'est gu\u00e9rir: savoir c'est gu\u00e9rir. https:\/\/www.savoir-c-guerir.com\/ (accessed Feb 17, 2020)."},{"key":"10.1016\/j.lanepe.2021.100281_bib0016","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2105\/AJPH.91.1.31","article-title":"Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness","volume":"91","author":"Rosenberg","year":"2001","journal-title":"Am J Public Health"},{"key":"10.1016\/j.lanepe.2021.100281_bib0017","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1002\/hep.20463","article-title":"Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure","volume":"40","author":"Di Martino","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.lanepe.2021.100281_bib0018","unstructured":"L\u00e9gifrance. Circulaire N\u00b0 DGOS\/R1\/R4\/DSS\/1A\/1C\/2A\/2015\/148 du 29 avril 2015 relative \u00e0 la facturation des antiviraux d'action directe (AAD) pour les patients pris en charge en ambulatoire dans des unit\u00e9s sanitaires en milieu p\u00e9nitentiaire. https:\/\/www.legifrance.gouv.fr\/circulaire\/id\/39572. 2021"},{"key":"10.1016\/j.lanepe.2021.100281_bib0019","article-title":"HCV reinfection rates after cure or spontaneous clearance among HIV-infected and uninfected men who have sex with men","author":"Adu","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.lanepe.2021.100281_bib0020","series-title":"\u00c9valuation des strat\u00e9gies de d\u00e9pistage des personnes infect\u00e9es par le VHC volet 1. \u00c9valuer l'efficience des strat\u00e9gies de d\u00e9pistage","year":"2019"},{"key":"10.1016\/j.lanepe.2021.100281_bib0021","first-page":"22","article-title":"Psychiatric care of patients with hepatitis C: a clinical update","volume":"32","author":"Thiara","year":"2015","journal-title":"Psychiatr Times"},{"key":"10.1016\/j.lanepe.2021.100281_bib0022","doi-asserted-by":"crossref","first-page":"230","DOI":"10.9740\/mhc.n132973","article-title":"How to increase medication adherence: what works?","volume":"2","author":"Ehret","year":"2013","journal-title":"Ment Health Clin"},{"key":"10.1016\/j.lanepe.2021.100281_bib0023","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1471-230X-13-86","article-title":"Psychiatric treatment considerations with direct acting antivirals in hepatitis C","volume":"13","author":"Sockalingam","year":"2013","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.lanepe.2021.100281_bib0024","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1136\/ejhpharm-2017-001352","article-title":"New direct-acting antivirals for hepatitis C treatment and neuropsychiatric symptoms in psychiatric risk groups","volume":"26","author":"Miarons","year":"2019","journal-title":"Eur J Hosp Pharm"},{"key":"10.1016\/j.lanepe.2021.100281_bib0025","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.encep.2020.03.003","article-title":"H\u00e9patite C en milieu psychiatrique: un r\u00e9servoir oubli\u00e9?","volume":"47","author":"Rolland","year":"2021","journal-title":"L'Enc\u00e9phale"}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776221002672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776221002672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T04:47:53Z","timestamp":1763009273000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666776221002672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":25,"alternative-id":["S2666776221002672"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2021.100281","relation":{},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of extending direct antiviral agents (DAA) availability in France: an observational cohort study (2015-2019) of data from French administrative healthcare databases (SNDS).","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2021.100281","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100281"}}